RTS, S/AS01 malaria vaccination with and without a booster was associated with vaccine
efficacies (VE) against clinical malaria of 18–36%(July 4, p 31). 1 Modelling has estimated …

In 2021, nearly half of the world's population lived at risk from malaria, with over 600 000
deaths annually, of which over 95% occur in the WHO African region and 80% of these in …

89: 233–35. 5 Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after
high-titre measles vaccine and association with subsequent vaccination with diphtheria …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

See Articles page 1543 An effective vaccine would have tremendous benefit for the
estimated 3 billion people living at risk of malaria. In today's Lancet, John Aponte and …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Summary Background The RTS, S/AS01 E malaria vaccine (RTS, S) was introduced by
national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale …

In October, 2021, WHO recommended that the RTS, S malaria vaccine, with its strong safety
profile and high impact, be provided to children from age 5 months in regions with moderate …

An initial 18 million doses of the world's first malaria vaccine are to be rolled out across 12
African countries in the next 2 years, announced Gavi, WHO, and UNICEF, on July 5. The …

No licensed vaccines are available for malaria or any other human parasitic disease. The
most advanced malaria vaccine candidate is RTS, S/AS01, which is directed against …